biote (NASDAQ:BTMD) Posts Quarterly Earnings Results, Beats Expectations By $0.01 EPS

biote (NASDAQ:BTMD) released its earnings results on Wednesday. The company reported $0.06 EPS for the quarter, topping the consensus estimate of $0.05 by $0.01, FiscalAI reports. The business had revenue of $46.41 million during the quarter, compared to analysts’ expectations of $45.79 million. biote had a negative return on equity of 21.86% and a net margin of 14.72%.

Here are the key takeaways from biote’s conference call:

• Management plans to expand the commercial team and increase sales personnel from over 90 to approximately 120 and invest in its technology platform to improve the practitioner experience; these moves are intended to drive long-term growth but will raise near-term expenses.
• Q4 revenue was $46.4 million, down 6.9% year-over-year, with procedure revenue falling 13% to $31.8 million, driven by higher clinic/practitioner attrition and fewer net new clinic additions.
• Dietary supplement revenue grew 16% to $11.7 million (e-commerce-led) and management expects mid- to high-single-digit supplement growth in 2026, highlighting a complementary revenue stream.
• A voluntary recall of specific hormone pellet lots caused a $1.3 million inventory charge in Q4 and could create near-term gross margin and supply impacts, though the company says it is working with the FDA to manage the situation.
• For 2026 management guided to revenues above $190 million and adjusted EBITDA greater than $38 million, forecasting procedure revenue to decline mid-to-high single digits in H1 before returning to growth in H2 as investments and sales hiring take effect.

biote Trading Up 1.2%

NASDAQ BTMD opened at $1.72 on Thursday. The business has a fifty day simple moving average of $2.20 and a 200 day simple moving average of $2.65. biote has a 12 month low of $1.68 and a 12 month high of $4.75. The firm has a market capitalization of $78.54 million, a P/E ratio of 2.18 and a beta of 1.14.

Institutional Investors Weigh In On biote

Institutional investors have recently added to or reduced their stakes in the company. LPL Financial LLC purchased a new position in shares of biote in the 4th quarter worth approximately $32,000. Quadrature Capital Ltd bought a new stake in biote during the fourth quarter worth $38,000. Marshall Wace LLP purchased a new position in biote in the fourth quarter worth $40,000. Millennium Management LLC purchased a new position in shares of biote in the 4th quarter worth about $40,000. Finally, AQR Capital Management LLC bought a new position in biote during the first quarter valued at about $43,000. 21.68% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. Weiss Ratings reissued a “sell (d+)” rating on shares of biote in a research note on Monday, December 29th. Truist Financial set a $5.00 price objective on shares of biote in a report on Wednesday, January 7th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, biote currently has an average rating of “Hold” and an average target price of $5.67.

biote News Roundup

Here are the key news stories impacting biote this week:

• Positive Sentiment: Q4 beat on the headline numbers — GAAP EPS $0.06 vs. $0.05 consensus and revenue $46.41M vs. $45.79M; net margin remained healthy (~14.7%), signaling underlying profitability. Zacks: Q4 Earnings and Revenues Top Estimates
• Positive Sentiment: Management projects 2026 revenue above $190M and is expanding the salesforce and investing in its tech platform — initiatives intended to drive longer-term top-line growth and recurring revenue. Seeking Alpha: Projects 2026 Revenue Above $190M
• Neutral Sentiment: Company press release frames 2025 as a “productive year” and reiterates strategic priorities (sales expansion, technology, practitioner network) intended to deliver sustainable, profitable growth. These are strategic positives but will take time to materialize. BusinessWire: Q4 and Full-Year 2025 Results
• Neutral Sentiment: Earnings call/transcript discusses “strategic growth amid revenue challenges” — management acknowledged near-term revenue headwinds while outlining investments; tone is constructive but cautious. Seeking Alpha: Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Reported short-interest data in the public feeds appears unreliable (zeros/NaN) and offers no clear signal on bearish positioning at this time.
• Negative Sentiment: FY2026 revenue guidance was set at ~$190M, below the consensus of ~$195.4M — the guidance miss is the primary near-term negative driver pressuring the stock despite the quarter’s slight beat. Press Release / Guidance Details

biote Company Profile

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.